细胞毒性T细胞
CD28
CD8型
癌症研究
医学
免疫疗法
生物
免疫系统
免疫学
遗传学
体外
作者
Alice O. Kamphorst,Andreas Wieland,Tahseen H. Nasti,Shu Yang,Ruan Zhang,Daniel L. Barber,Bogumila T. Konieczny,Candace Daugherty,Lydia Koenig,Yu Ke,Gabriel Sica,Arlene H. Sharpe,Gordon J. Freeman,Bruce R. Blazar,Laurence A. Turka,Taofeek K. Owonikoko,Rathi N. Pillai,Suresh S. Ramalingam,Koichi Araki,Rafi Ahmed
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2017-03-09
卷期号:355 (6332): 1423-1427
被引量:1034
标识
DOI:10.1126/science.aaf0683
摘要
Programmed cell death-1 (PD-1)-targeted therapies enhance T cell responses and show efficacy in multiple cancers, but the role of costimulatory molecules in this T cell rescue remains elusive. Here, we demonstrate that the CD28/B7 costimulatory pathway is essential for effective PD-1 therapy during chronic viral infection. Conditional gene deletion showed a cell-intrinsic requirement of CD28 for CD8 T cell proliferation after PD-1 blockade. B7-costimulation was also necessary for effective PD-1 therapy in tumor-bearing mice. In addition, we found that CD8 T cells proliferating in blood after PD-1 therapy of lung cancer patients were predominantly CD28-positive. Taken together, these data demonstrate CD28-costimulation requirement for CD8 T cell rescue and suggest an important role for the CD28/B7 pathway in PD-1 therapy of cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI